Dual therapy with vedolizumab and tofacitinib in refractory ulcerative colitis patients – single centre experience

Posted by Michael Jannicelli | Feb 9, 2026 | Uncategorized | 0 |

$Dual therapy with vedolizumab and tofacitinib in refractory ulcerative colitis patients – single centre experience$

Dual therapy with vedolizumab and tofacitinib in refractory ulcerative colitis patients – single centre experience

M Kolar ,
K Kastylova ,
M Lukas ,
D Duricova ,
V Hruba ,
N Machkova ,
K Cerna ,
J Jirsa ,
K Kubickova ,
G Vojtechova
… Show more
Journal of Crohn’s and Colitis, Volume 17, Issue Supplement_1, February 2023, Page i538, https://doi.org/10.1093/ecco-jcc/jjac190.0538…

Michael Jannicelli

Michael Jannicelli - "A PROVEN BUSINESS FIRESTARTER & BRANDING GENIUS" a true natural born Trendsetter. • Created over 100 products under 3 brands, sold in 30+ countries worldwide and influencing youth across the globe. • Featured in Forbes magazine +over 100 print publications, television talk shows, major motion pictures and national radio stations. • Co-founder and VP of Bliss beverage USA and President/co-founder of Socko International - fastest growing privately held beverage company in US (Forbes) with Hogan Energy & Raw Energy WWE. • Co-founder of Throwdown Industries (2003) - leading brand in multibillion dollar Impact/Action Sports Market (products designed for superior MN • Diagnosed with auto-immune diseases aged 13; using his experience to help others and promote a positive message while developing edgy products to benefit people with chronic illness.